Randomized Double-Blind Phase II Study of Radioactive Iodine (RAI) in Combination With Placebo or Selumetinib for the Treatment of RAI-Avid Recurrent/Metastatic Thyroid Cancers
Phase of Trial: Phase II
Latest Information Update: 06 Oct 2017
At a glance
- Drugs Selumetinib (Primary) ; Iodine-131
- Indications Thyroid cancer
- Focus Therapeutic Use
- 02 Oct 2017 Planned number of patients changed from 100 to 60.
- 10 Mar 2016 Planned number of patients changed from 94 to 100, according to ClinicalTrials.gov record.
- 16 Dec 2015 Status changed from suspended to recruiting as per ClinicalTrials.gov record.